ImmunityBio Shares Track Weekly Loss Despite Early FDA Approval for Anktiva
ImmunityBio Inc (IBRX) gained expanded U.S. Food and Drug Administration approval for its immunotherapy drug Anktiva to treat adults with BCG-unresponsive non-muscle-invasive bladder cancer featuring papillary-only tumors. The decision arrived nearly three months ahead of the planned target decision date. On Wednesday, the stock rose 1.12% to close at $9.91, though shares remain on track for a 6% weekly decline.
The regulatory expansion broadens Anktiva's reach, as papillary disease represents approximately 85% of non-muscle-invasive bladder cancer cases. Combined with Bacillus Calmette-Guerin, Anktiva becomes the first FDA-approved therapy specifically for papillary-only disease in this patient group. The regimen previously received a Category 2A recommendation in medical guidelines earlier this year and holds regulatory authorizations across 34 countries.
Investors are focusing on an upcoming Friday discussion where founder Patrick Soon-Shiong will discuss ongoing clinical trials, including the QUILT-2.005 study evaluating Anktiva in patients who have not previously received BCG. The company plans to submit a supplemental regulatory application for BCG-naive patients in 2026.
Key points
- The FDA expanded Anktiva's approval to cover BCG-unresponsive bladder cancer with papillary-only tumors almost three months ahead of schedule.
- Papillary disease accounts for about 85% of non-muscle-invasive bladder cancer cases, expanding Anktiva's U.S. patient population.
- ImmunityBio stock rose 1.12% on Wednesday to close at $9.91 but remains down 6% for the week.
- Founder Patrick Soon-Shiong is set to discuss clinical trial status during a fireside chat on Friday.
- ImmunityBio plans to submit a supplemental application for BCG-naive bladder cancer patients in 2026.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the new FDA approval for ImmunityBio Anktiva?
The FDA expanded approval for Anktiva to treat adults with BCG-unresponsive non-muscle-invasive bladder cancer who have papillary-only tumors, administered alongside BCG.
Why is ImmunityBio stock down despite the FDA decision?
Despite gaining early regulatory approval and closing 1.12% higher on Wednesday at $9.91, ImmunityBio stock remains down 6% for the week as investors await further clinical trial updates.
When will ImmunityBio provide its next clinical trial update?
Founder Patrick Soon-Shiong is scheduled to discuss the status of clinical trials during a fireside chat on Friday.